Cover Image

A clinical study of dyslipidemia in patients of chronic kidney disease

Gourav Garg, Sumit Pal Singh Chawla*, Sarabjot Kaur


Cardiovascular disease is a major cause of morbidity and mortality in patients with Chronic Kidney Disease (CKD). Patients with CKD exhibit significant alterations in lipoprotein metabolism, which in their most advanced form may result in the development of severe dyslipidemia which can lead to increased risk of cardiovascular complications. The K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines suggest that all CKD patients should therefore be evaluated for dyslipidemia. Hence this study was undertaken to know the prevalence of dyslipidemia in CKD patients and thereby assess the impending risk of cardiovascular morbidity in these patients. This study was carried out in 100 CKD patients and it was observed that the mean values of Triglycerides (TG), Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), TC/HDL, LDL/HDL were increased and High Density Lipoprotein Cholesterol (HDL-C) was decreased in the patients under study. There was also statistically significant increase in the values of TG, TC, VLDL-C and TC/HDL with the progression of the disease (stage of CKD). Early recognition of dyslipidemia in CKD patients and maintenance of desired lipid levels either through diet or lipid lowering drugs can be helpful in decreasing the risk of cardiovascular complications in these patients.


Chronic Kidney Disease; dyslipidemia; cardiovascular disease; TG; TC; LDL-C; VLDL-C; HDL-C.

Full Text:



Gupta R, Trends in hypertension epidemiology in India, J Hum Hypertens, 2004, 18(2), 73–8.

Kher V, End-stage renal disease in developing countries, Kidney Int, 2002, 62(1), 350–62.

Foley RN, Parfrey PS, Sarnak MJ, Clinical epidemiology of cardiovascular disease in chronic renal disease, Am J Kidney Dis, 1998, 32, 112-9.

Attman PO, Samuelsson O, Alaupovic P, Lipoprotein metabolism and renal failure, Am J Kidney Dis, 1993, 21, 573 –92.

Moorehead JF, Chan MK, Varghese Z, Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease, Lancet, 2002, 11, 1309–11.

Bhagwat R, Joshi SP, Salgia P, Lipid abnormality in chronic renal failure, Indian Journal of Clinical Biochemistry, 1997, 12(1), 81-5.

Bhansali AS, Kumbhalkar SD, Salkar HR, Dyslipidemia in patients of chronic renal failure on dialysis, J Assoc phy India, 2003, 51, 1272-4.

Massy ZA, Khoa TN, Lacour B, Dyslipidemia and progression of renal disease in chronic renal failure patients, Nephrol Dial Transplant, 1999, 14, 2392-7.

Ljutfi Z, Koco C, Todor G, Lipid profile and concentration of ApoA-1 and ApoB-100 in patients with end-stage renal disease treated by repeated hemodialysis, Sec Biol Med Sci, 2008, 29, 141-52.

Kaysen GA, Hyperlipidemia of chronic renal failure, Blood Purif, 1994, 12, 60-7.

Peck LW, Monsen ER, Ahmad S, Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients, Am J Clin Nut, 1996, 64, 210-4.

Fliser D, Pacini G, Engelleiter R, Insulin resistance and hyperinsulinemia in patients with incipient renal disease, Kidney Int, 1998, 53, 1343-7.

Moberly JB, Attman PO, Samuelsson O, Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia, Miner Electrolyte Metab, 1999, 25, 258-62.

Attman PO, Alaupovic P, Tavella M, Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure, Nephrol Dial Transplant, 1996, 11, 65-9.

Tsumura M, Kinouchi T, Ono S, Serum lipid metabolism abnormalities and changes in lipoprotein contents in patients with advanced-stage renal disease, CCA, 2001, 314, 27-37.

Kasiske BL, Hyperlipidemia in patients with chronic renal disease, Am J Kidney Dis, 1998, 32, 142-56.

Deighan CJ, Caslake MJ, McConnell M, Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation, Am J Kidney Dis, 2000, 35, 852-62.

Bagdade J, Casaretto A, Albers J, Effects of chronic uremia, hemodialysis and renal transplantation on plasma lipids and lipoproteins in man, J Clin lab med, 1976, 87(1), 37-47.

Ikewaki K, Schaefer JR, Frischmann ME, Delayed in vivo catabolism of intermediate-density lipoprotein and Lowdensity lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis, Arterioscler Thromb Vasc Biol, 2005, 25, 2615–22.

Morena M, Cristol JP, Dantoine T, Protective effects of high-density lipoprotein against oxidative stress are impaired in hemodialysis patients, Nephrol Dial Transplant, 2000, 15, 389-95.

Vaziri ND, Deng G, Liang K, Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure, Nephrol Dial Transplant, 1999, 14, 1462-6.

Vaziri ND, Liang K, Parks JS, Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure, Kidney Int, 2001, 59, 2192-6.

Appel G, Lipid abnormalities in renal disease, Kidney Int, 1991, 39, 169–83.

Cheung AK, Wu LL, Kablitz C, Atherogenic lipids and lipoproteins in hemodialysis patients, Am J Kidney Dis, 1993, 22(2), 271-6.

Avram MM, Goldwasser P, Burrell DE, The uremic dyslipidemia: a cross sectional and longitudinal study, Am J Kidney Dis, 1992, 20(4), 324- 35.



  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.